A
-
Abbas, Neven
Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
-
Abdel-Razik, Ahmed
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
-
Ali, Sarah
Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
-
Attia, Attia Ahmed
Screening of Occult Hepatitis B Virus Infection among Egyptian Blood Donors. [5.2, Issue 2, 2021, Pages 27-31]
E
-
Ehab, Ahmed
Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
-
Elbadrawy, Tasnim
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
-
El-gharabawy, Sahar
Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
-
Elhelaly, Rania
Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
-
Elmetwalli, Alaa
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
-
Elmetwalli, Alaa
Screening of Occult Hepatitis B Virus Infection among Egyptian Blood Donors. [5.2, Issue 2, 2021, Pages 27-31]
H
-
Habeeb, Maha R.
Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
-
Habeeb, Maha R
Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
-
Hosni, Khaled
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
M
-
Mahmoud, Alaa N
Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
-
Menesy, Ayman
Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
-
Mohamed, Farag
Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
-
Mousa, Aya
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
-
Mousa, Eman
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
-
Mousa, Nasser
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
S
-
Sabry, Mohammed
Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
-
Saed, Ahmed
Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
-
Selim, Mahmoud
Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
-
Sheta, Tarek
Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
-
Shiha, Gamal
Misuse of anticoagulants in COVID-19 patient: A case of gastrointestinal bleeding [5.2, Issue 2, 2021, Pages 1-2]
-
Soliman, Reham
Misuse of anticoagulants in COVID-19 patient: A case of gastrointestinal bleeding [5.2, Issue 2, 2021, Pages 1-2]
T
-
Taha, Ahmed
Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
Your query does not match with any item